HKSE · 2162.HK
Keymed Biosciences Inc.
HK$67.00+HK$0.10 (+0.15%)
Keymed Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.35% below the high.
Loading market information…
HKSE · 2142.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
HBM Holdings Limited’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HBM Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$321.36M-51.19% vs estimate |
| Q4 2022 | Mar 29, 2023 | -HK$0.70 | HK$101.66M-97.91% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$67.00+HK$0.10 (+0.15%)
Keymed Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.35% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$18.12-HK$0.48 (-2.58%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 37.9% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$36.80-HK$0.18 (-0.49%)
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.26% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$3.21+HK$0.14 (+4.57%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.42% below the high.
HK$26.10-HK$0.34 (-1.29%)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 22.78% below the high.
